Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.

Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.

Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace Directory

Revvity launches IDS i20 platform from Euroimmun

August 2025—Revvity announced the launch of its IDS i20 analytical random access platform from Euroimmun, enabling full automation of chemiluminescence immunoassays. The CE-marked and FDA-listed IDS i20 allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. The specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer’s disease, and therapeutic drug monitoring. The instrument can process up to 140 tests per hour and features continuous loading of samples and reagents as well as integrated cooling of ready-to-use reagent cartridges. It is for in vitro diagnostic use.

Precision Epigenomics presents Episeek MCED test results at ASCO

August 2025—Precision Epigenomics presented validation data for its flagship multicancer early detection (MCED) test, Episeek, at the 2025 ASCO annual meeting in Chicago, May 30–June 3. The data demonstrated that the blood-based test is capable of identifying more than 60 cancer types with a 99.5 percent specificity rate and a turnaround time of two to three days. The test was validated on 281 cancer-positive plasma samples across all four stages and 201 samples from healthy people over 40 years old. It showed a 45 percent sensitivity for stage I/II cancers and a 74 percent sensitivity for stage IV cancers, with positive and negative predictive values of 64.9 percent and 99.5 percent, respectively.

Qiagen launches QIAseq, QIAcuity products

August 2025—Qiagen announced a series of product and partnership updates, including a new set of QIAseq panels for comprehensive genomic profiling, a QIAcuity digital PCR kit and assays for cell and gene therapy quality control, and a free, limited version of the Human Somatic Mutation Database from the Qiagen Digital Insights bioinformatics business.

CytoChip showcases CLIA-waived CitoCBC at ADLM

August 2025—CytoChip showcased its flagship product, CitoCBC, a cartridge-based CBC analyzer, at the Association for Diagnostics and Laboratory Medicine annual meeting, July 27–31, in Chicago. CitoCBC delivers rapid CBC results with a five-part white blood cell differential from a cartridge-based system and requires only monthly quality control.

FDA approves Randox ConcizuTrace ELISA CDx

July 2025—The Food and Drug Administration has approved the de novo application for Randox Laboratories’ first companion diagnostic, the Randox ConcizuTrace ELISA. The test, developed in collaboration with Novo Nordisk, is intended for the quantitative measurement of concizumab-mtci concentration in human 3.2 percent citrated plasma samples from patients with hemophilia A and B four weeks after the initiation of treatment. The measurement of the concentration is used for dose adjustment decision in accordance with the drug label.

Bio-Rad presents workshops, demos at ADLM 2025

July 2025—Bio-Rad Laboratories will present an array of clinical diagnostic-related offerings at this year’s Association for Diagnostics and Laboratory Medicine Clinical Lab Expo in Chicago, July 27–31. An industry workshop titled “From Waste to Wow: Optimizing Your Quality Control Workflow” is designed to provide attendees with strategies to streamline QC management across multihospital systems for systemwide efficiency, reduce waste streams in clinical chemistry, and recognize patient-based real-time QC to improve lab QC processes.

StaffReady launches mobile app, website

July 2025—StaffReady has released a mobile app for its StaffReady Scheduling. The app is available on Apple and Android devices and offers StaffReady’s Calendar feature for users to easily view a schedule, request PTO, or make detailed shift requests, such as giveaways, trades, or bids. In addition, the company offers a weekly educational newsletter on its new website. It provides content specific to ancillary markets such as laboratories, pharmacies, and physical therapy/rehab departments and focuses on trends that affect workforce management in health care.

BD gets FDA 510(k) clearance for advanced microbiology solution

July 2025—BD announced FDA 510(k) clearance for the BD Phoenix M50 automated microbiology solution and BDXpert system on the BD Synapsys informatics solution, leveraging rapid identification and antimicrobial susceptibility testing algorithms to assist in interpreting complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance. BDXpert is an automated, rule-based system that analyzes ID and AST results from the BD Phoenix M50 system.

Techcyte launches wet mount iodine solution

July 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States. The AI-assisted screening tool is designed to help users locate, count, and preclassify parasites from iodine-stained fecal slides. The solution is part of Techcyte’s Fusion parasitology suite, which includes the company’s trichrome and modified acid fast solutions.

BioMérieux acquires Day Zero Diagnostics

July 2025—BioMérieux has agreed to acquire Day Zero Diagnostics, an infectious disease diagnostics company, with the aim of enhancing BioMérieux’s capabilities in next-generation sequencing and rapid diagnostics. Day Zero Diagnostics, based in Watertown, Mass., has developed technologies that integrate direct from whole blood sample preparation, sequencing, and advanced infectious disease and antimicrobial susceptibility testing analytics. The sequencing-based rapid diagnostic in development can identify the species and antibiotic resistance profile of a bacterial pathogen within hours.

MARKETPLACE

TRENDING